Final results from randomized phase II trial of preoperative docetaxel (D) and capecitabine (C) given sequentially or concurrently for HER2-negative breast cancers.
A. B. Zelnak
No relevant relationships to disclose
S. Harichand-Herdt
No relevant relationships to disclose
T. M. Styblo
No relevant relationships to disclose
M. Rizzo
No relevant relationships to disclose
S. G. A. Gabram
No relevant relationships to disclose
H. L. Bumpers
No relevant relationships to disclose
R. C. Hermann
No relevant relationships to disclose
J. Srinivasiah
No relevant relationships to disclose
F. M. Schnell
No relevant relationships to disclose
R. O'Regan
No relevant relationships to disclose